drugset / Trial / NCT07668232
Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation
RandomizedParallel-groupOpen-labelTreatment
Summary
Posterior urethral valve is the main cause of bladder outlet obstruction in male infants and the most common cause of obstructive uropathy leading to chronic renal failure and end-stage renal disease in children.The incidence of posterior urethral valve is approximately 1:7,000-8,000 live births.
Timeline
- Start
- 2025-01-01
- Primary completion
- 2025-12-15
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirabegron | Other / unclassified | 0.5 mg/kg | Oral |
| Comparator | Mirabegron | Other / unclassified | 1 mg/kg | Oral |
| Comparator | Oxybutynin | Small molecule | 0.2 mg/kg | Oral |